Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 48
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Br J Surg ; 99(8): 1149-54, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22718521

RESUMEN

BACKGROUND: Various definitions are used to calculate postoperative mortality. As variation hampers comparability between reports, a study was performed to evaluate the impact of using different definitions for several types of cancer surgery. METHODS: Population-based data for the period 1997-2008 were retrieved from the Rotterdam Cancer Registry for resectional surgery of oesophageal, gastric, colonic, rectal, breast, lung, renal and bladder cancer. Postoperative deaths were tabulated as 30-day, in-hospital or 90-day mortality. Postdischarge deaths were defined as those occurring after discharge from hospital but within 30 days. RESULTS: This study included 40,474 patients. Thirty-day mortality rates were highest after gastric (8·8 per cent) and colonic (6·0 per cent) surgery, and lowest after breast (0·2 per cent) and renal (2·0 per cent) procedures. For most tumour types, the difference between 30-day and in-hospital rates was less than 1 per cent. For bladder and oesophageal cancer, however, the in-hospital mortality rate was considerably higher at 5·1 per cent (+1·3 per cent) and 7·3 per cent (+2·8 per cent) respectively. For gastric, colonic and lung cancer, 1·0 per cent of patients died after discharge. For gastric, lung and bladder cancer, more than 3 per cent of patients died between discharge and 90 days. CONCLUSION: The 30-day definition is recommended as an international standard because it includes the great majority of surgery-related deaths and is not subject to discharge procedures. The 90-day definition, however, captures mortality from multiple causes; although this may be of less interest to surgeons, the data may be valuable when providing information to patients before surgery.


Asunto(s)
Neoplasias/mortalidad , Complicaciones Posoperatorias/mortalidad , Mortalidad Hospitalaria , Humanos , Neoplasias/cirugía , Países Bajos/epidemiología , Sistema de Registros , Análisis de Supervivencia
2.
Ann Surg Oncol ; 17(6): 1682-7, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20333552

RESUMEN

INTRODUCTION: Despite high response rates to systemic chemotherapy, 30% of patients with advanced stage testicular carcinoma will have extra-retroperitoneal residual masses that require resection. Most often, these are located in the lungs and mediastinum and neck. Limited data are available concerning the incidence, surgical management, and follow-up of neck metastasis arising from a testicular primary tumor. METHODS: We retrospectively reviewed all 665 patients who were referred to a tertiary referral center with the diagnosis of testicular cancer from January 1997 to June 2009 for the presence of cervical metastases. Patients who underwent concomitant surgical therapy were identified and analyzed. Clinical and pathological data were collected from patient records, including radiology and pathology reports. Furthermore, data on primary treatment strategy, chemotherapeutic regimens, timing of surgical procedures, complications, disease recurrence, and follow-up were collected. RESULTS: Twenty-six patients (4%) had cervical lymph node metastasis. The majority (n = 19) had multiple ERP sites. Nine patients (35%) underwent selective neck dissection: in six patients, this was indicated because of residual masses after chemotherapy, and in three patients, cervical masses represented a late and distant relapse of previously treated disease. Viable cancer cells were present in the resected specimen only in these three patients. Seven patients are currently without evidence of disease. Two patients died of disseminated disease. CONCLUSIONS: Cervical lymph node metastases originating from testicular cancer are rare but are more commonly observed in patients with advanced stage disease. Selective neck dissection can be safely performed both after chemotherapy and in the case of recurrent disease.


Asunto(s)
Neoplasias de Cabeza y Cuello/cirugía , Disección del Cuello , Neoplasias Testiculares/cirugía , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Estudios de Seguimiento , Neoplasias de Cabeza y Cuello/secundario , Hospitales Universitarios , Humanos , Metástasis Linfática , Masculino , Persona de Mediana Edad , Disección del Cuello/métodos , Estadificación de Neoplasias , Estudios Retrospectivos , Neoplasias Testiculares/tratamiento farmacológico , Neoplasias Testiculares/patología , Resultado del Tratamiento
3.
Eur J Surg Oncol ; 46(6): 1160-1166, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32122756

RESUMEN

INTRODUCTION: Surgery for locally advanced rectal cancer (LARC) or locally recurrent rectal cancer (LRRC) may require total pelvic exenteration with the need for urinary diversion. The aim of this study was to describe outcomes for ileal and colon conduits after surgery for LARC and LRRC. METHODS: All consecutive patients from two tertiary referral centers who underwent total pelvic exenteration for LARC or LRRC between 2000 and 2018 with cystectomy and urinary reconstruction using an ileal or colon conduit were retrospectively analyzed. Short- (≤30 days) and long-term (>30 days) complications were described for an ileal and colon conduit. RESULTS: 259 patients with LARC (n = 131) and LRRC (n = 128) were included, of whom 214 patients received an ileal conduit and 45 patients a colon conduit. Anastomotic leakage of the ileo-ileal anastomosis occurred in 9 patients (4%) after performing an ileal conduit. Ileal conduit was associated with a higher rate of postoperative ileus (21% vs 7%, p = 0.024), but a lower proportion of wound infections than a colon conduit (14% vs 31%, p = 0.006). The latter did not remain significant in multivariate analysis. No difference was observed in the rate of uretero-enteric anastomotic leakage, urological complications, mortality rates, major complications (Clavien-Dindo≥3), or hospital stay between both groups. CONCLUSION: Performing a colon conduit in patients undergoing total pelvic exenteration for LARC or LRRC avoids the risks of ileo-ileal anastomotic leakage and may reduce the risk of a post-operative ileus. Besides, there are no other differences in outcome for ileal and colon conduits.


Asunto(s)
Colon/cirugía , Cistectomía/métodos , Íleon/cirugía , Recurrencia Local de Neoplasia/cirugía , Neoplasias del Recto/cirugía , Vejiga Urinaria/cirugía , Derivación Urinaria/métodos , Anciano , Anastomosis Quirúrgica , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/diagnóstico , Estadificación de Neoplasias , Neoplasias del Recto/diagnóstico , Estudios Retrospectivos , Reservorios Urinarios Continentes
4.
World J Surg ; 33(7): 1502-8, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19421811

RESUMEN

INTRODUCTION: Complete resection is the most important prognostic factor in surgery for pelvic tumors. In locally advanced and recurrent pelvic malignancies, radical margins are sometimes difficult to obtain because of close relation to or growth in adjacent organs/structures. Total pelvic exenteration (TPE) is an exenterative operation for these advanced tumors and involves en bloc resection of the rectum, bladder, and internal genital organs (prostate/seminal vesicles or uterus, ovaries and/or vagina). METHODS: Between 1994 and 2008, a TPE was performed in 69 patients with pelvic cancer; 48 with rectal cancer (32 primary and 16 recurrent), 14 with cervical cancer (1 primary and 13 recurrent), 5 with sarcoma (3 primary and 2 recurrent), 1 with primary vaginal, and 1 with recurrent endometrial carcinoma. Ten patients were treated with neoadjuvant chemotherapy and 66 patients with preoperative radiotherapy to induce down-staging. Eighteen patients received IORT because of an incomplete or marginal complete resection. RESULTS: The median follow-up was 43 (range, 1-196) months. Median duration of surgery was 448 (range, 300-670) minutes, median blood loss was 6,300 (range, 750-21,000) ml, and hospitalization was 17 (range, 4-65) days. Overall major and minor complication rates were 34% and 57%, respectively. The in-hospital mortality rate was 1%. A complete resection was possible in 75% of all patients, a microscopically incomplete resection (R1) in 16%, and a macroscopically incomplete resection (R2) in 9%. Five-year local control for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 89%, 38%, and 64%, respectively. Overall survival after 5 years for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 66%, 8%, and 45%. CONCLUSIONS: Total pelvic exenteration is accompanied with considerable morbidity, but good local control and acceptable overall survival justifies the use of this extensive surgical technique in most patients, especially patients with primary locally advanced rectal cancer and recurrent cervical cancer.


Asunto(s)
Invasividad Neoplásica/patología , Recurrencia Local de Neoplasia/mortalidad , Exenteración Pélvica/métodos , Neoplasias Pélvicas/mortalidad , Neoplasias Pélvicas/cirugía , Adulto , Anciano , Braquiterapia/métodos , Estudios de Cohortes , Supervivencia sin Enfermedad , Neoplasias Endometriales/mortalidad , Neoplasias Endometriales/patología , Neoplasias Endometriales/radioterapia , Neoplasias Endometriales/cirugía , Femenino , Mortalidad Hospitalaria/tendencias , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Análisis Multivariante , Recurrencia Local de Neoplasia/patología , Recurrencia Local de Neoplasia/radioterapia , Estadificación de Neoplasias , Exenteración Pélvica/efectos adversos , Neoplasias Pélvicas/patología , Neoplasias Pélvicas/radioterapia , Complicaciones Posoperatorias/mortalidad , Probabilidad , Pronóstico , Modelos de Riesgos Proporcionales , Calidad de Vida , Radioterapia Adyuvante , Neoplasias del Recto/mortalidad , Neoplasias del Recto/patología , Neoplasias del Recto/radioterapia , Neoplasias del Recto/cirugía , Estudios Retrospectivos , Medición de Riesgo , Análisis de Supervivencia , Neoplasias del Cuello Uterino/mortalidad , Neoplasias del Cuello Uterino/patología , Neoplasias del Cuello Uterino/radioterapia , Neoplasias del Cuello Uterino/cirugía
5.
Eur J Surg Oncol ; 44(10): 1548-1554, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-30075979

RESUMEN

BACKGROUND: Total pelvic exenteration (TPE) is a radical approach for locally advanced rectal cancer (LARC) and locally recurrent rectal cancer (LRRC) in case of tumour invasion into the urogenitary tract. The aim of this study is to assess surgical and oncological outcomes of TPE for LARC and LRRC in elderly patients compared to younger patients. METHODS: All patients who underwent TPE for LARC and LRRC between January 1990 and March 2017 were retrospectively analyzed. Patients aged <70 years were classified as younger and ≥70 years as elderly patients. RESULTS: In total 126 patients underwent TPE, of whom 88 younger and 38 elderly patients. Elderly patients had a significantly higher number of ASA > II patients (p = 0.01). Indication for surgery LARC (n = 73) and LRRC (n = 53) did not differ significantly. The 30-day mortality rate was significantly higher (p = 0.01) in elderly (13%) compared to younger patients (3%). Elderly patients experienced more anastomotic leakage (p = 0.02). Median overall survival (OS) was 75 months [95%CI 37.1; 112.9] for elderly and 45 months [95%CI 22.4; 67.8] for younger patients (p = 0.77). The 5-year OS rate was 44% in both groups. Median disease specific survival (DSS) was 78 months [95%CI 69.1; 86.9] for elderly and 60 months [95%CI 36.6; 83.4] for younger patients (p = 0.34). The 5-year DSS rate was 57% and 49%, respectively. CONCLUSION: TPE is an invasive treatment for rectal cancer with high 30-day mortality in elderly patients. Oncological outcomes are similar in elderly and younger patients. Therefore, TPE should not be withheld because of high age only, but careful patient selection is needed.


Asunto(s)
Recurrencia Local de Neoplasia/cirugía , Exenteración Pélvica/efectos adversos , Neoplasias del Recto/cirugía , Factores de Edad , Anciano , Fuga Anastomótica/etiología , Quimioradioterapia Adyuvante , Humanos , Persona de Mediana Edad , Terapia Neoadyuvante , Invasividad Neoplásica , Recurrencia Local de Neoplasia/patología , Recurrencia Local de Neoplasia/terapia , Neoplasia Residual , Exenteración Pélvica/mortalidad , Neoplasias del Recto/patología , Neoplasias del Recto/terapia , Estudios Retrospectivos , Tasa de Supervivencia
6.
Eur J Surg Oncol ; 33(4): 452-8, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17071043

RESUMEN

AIMS: To report the role of total pelvic exenteration in a series of locally advanced and recurrent rectal cancers. METHODS: In the period 1994-2004, TPE was performed in 35 of 296 patients with primary locally advanced and recurrent rectal cancer treated in the Daniel den Hoed Cancer Center; 23 of 176 with primary locally advanced and 12 of 120 with recurrent rectal cancer. All but one patient received pre-operative External Beam Radiation Therapy (EBRT). After 1997, Intra Operative Radiotherapy (IORT) was performed in case of a resection margin less than 2 mm. RESULTS: Overall major complication rates were not significantly different between patients with primary and recurrent rectal cancer (26% vs. 50%, p=0.94). The hospital mortality rate was 3%. The 5-year local control and overall survival of patients with primary locally advanced rectal cancer were 88% and 52%, respectively. In patients with recurrent rectal cancer 3-year local control and survival rates were 60% and 32%, respectively. An incomplete resection, preoperative pain and advanced Wanebo stage for recurrent cancer were negative prognostic factors for both local control and overall survival. CONCLUSION: TPE in primary locally advanced rectal cancer enables good local control and acceptable overall survival, thereby justifying the use of the procedure. Patients with recurrent rectal cancer showed a high rate of major complications, a high distant metastasis rate, and a poor overall survival.


Asunto(s)
Exenteración Pélvica/métodos , Neoplasias del Recto/cirugía , Adulto , Anciano , Terapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/radioterapia , Recurrencia Local de Neoplasia/cirugía , Estadificación de Neoplasias , Complicaciones Posoperatorias , Pronóstico , Modelos de Riesgos Proporcionales , Neoplasias del Recto/patología , Neoplasias del Recto/radioterapia , Tasa de Supervivencia , Resultado del Tratamiento
7.
J Natl Cancer Inst ; 90(12): 925-31, 1998 Jun 17.
Artículo en Inglés | MEDLINE | ID: mdl-9637143

RESUMEN

BACKGROUND: Population-based screening for prostate cancer is currently being evaluated in randomized clinical trials in the United States and in Europe. Side effects arising from the process of screening and from the earlier treatment of screen-detected prostate cancer may be important factors in the evaluation. To examine health-related quality of life (or health status) among men screened for prostate cancer, we conducted a longitudinal study of 626 attenders to the Rotterdam (The Netherlands) prostate cancer screening program and of 500 nonparticipants. METHODS: Attenders of the screening program and nonparticipants completed self-assessment questionnaires (SF-36 [i.e., Medical Outcomes Study 36-Item Short-Form Health Survey] and EQ-5D [i.e., EuroQol measure for health-related quality of life] health surveys) to measure generic health status, as well as an additional questionnaire for anxiety and items relating to prostate cancer screening. RESULTS: Physical discomfort during digital rectal examination and during transrectal ultrasound was reported by 181 (37%) of 491 men and by 139 (29%) of 487 men, respectively; discomfort during prostate biopsy was reported by 64 (55%) of 116 men. Mean scores for health status and anxiety indicated that the participants did not experience relevant changes in physical, psychological, and social functioning during the screening procedure. However, high levels of anxiety were observed throughout the screening process among men with a high predisposition to anxiety. Similar scores for anxiety predisposition were observed among attenders and nonparticipants. CONCLUSIONS: At the group level, we did not find evidence that prostate cancer screening induced important short-term health-status effects, despite the short-lasting side effects related to the biopsy procedure. However, subgroups may experience high levels of anxiety. The implication is that unfavorable health-status effects of prostate cancer screening occur mainly in the treatment phase.


Asunto(s)
Estado de Salud , Tamizaje Masivo/efectos adversos , Neoplasias de la Próstata/parasitología , Calidad de Vida , Ansiedad/etiología , Humanos , Estudios Longitudinales , Masculino , Países Bajos , Neoplasias de la Próstata/psicología , Encuestas y Cuestionarios
8.
Cancer Res ; 61(4): 1265-8, 2001 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-11245416

RESUMEN

We analyzed the possible prognostic value of the recently discovered fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer. A FGFR3 mutation was found in 34 of 53 pTaG1-2 bladder cancers, whereas none of the 19 higher-staged tumors had a mutation (P < 0.0001). In 57 patients with superficial disease followed prospectively by cystoscopy for 12 months, 14 of 23 patients in the wild-type FGFR3 group developed recurrent bladder cancer compared with only 7 of 34 patients in the mutant group (P = 0.004). The recurrence rate per year was 0.24 for the FGFR3 mutant tumors and 1.12 for tumors with a wild-type FGFR3 gene. In addition, FGFR3 mutation status was the strongest predictor of recurrence when compared with stage and grade (P = 0.008). This is the first mutation in bladder cancer that selectively identifies patients with favorable disease characteristics. Our results suggest that the frequency of cystoscopic examinations can be reduced considerably in patients with FGFR3-positive tumors.


Asunto(s)
Mutación , Recurrencia Local de Neoplasia/genética , Proteínas Tirosina Quinasas , Receptores de Factores de Crecimiento de Fibroblastos/genética , Neoplasias de la Vejiga Urinaria/genética , Adulto , Anciano , Anciano de 80 o más Años , Análisis Mutacional de ADN , ADN de Neoplasias/genética , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/patología , Estadificación de Neoplasias , Reacción en Cadena de la Polimerasa/métodos , Pronóstico , Estudios Prospectivos , Receptor Tipo 3 de Factor de Crecimiento de Fibroblastos , Neoplasias de la Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria/cirugía
9.
J Clin Oncol ; 19(6): 1619-28, 2001 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-11250990

RESUMEN

PURPOSE: The current study was undertaken within the framework of a screening trial to compare the health-related quality-of-life (HRQOL) outcomes of two primary treatment modalities for localized prostate cancer: radical prostatectomy and external-beam radiotherapy. PATIENTS AND METHODS: We conducted a prospective longitudinal cohort study among 278 patients with early screen-detected (59%) or clinically diagnosed (41%) prostate cancer using both generic and disease-specific HRQOL measures (SF-36, UCLA Prostate Cancer Index [urinary and bowel modules] and items relating to sexual functioning) at three points in time: t1 (baseline), t2 (6 months later), and t3 (12 months after t1). RESULTS: Questionnaires were completed by 88% to 93% of all initially enrolled patients. Patients referred for primary radiotherapy were significantly older than prostatectomy patients (63 v 68 years, P <.01). Analyses (adjusted for age and pretreatment level of functioning) revealed poorer levels of generic HRQOL after radiotherapy. Prostatectomy patients reported significantly higher (P <.01) posttreatment incidences of urinary incontinence (39% to 49%) and erectile dysfunction (80% to 91%) than radiotherapy patients (respectively, 6% to 7% and 41% to 55%). Bowel problems (urgency) affected 30% to 35% of the radiotherapy group versus 6% to 7% of the prostatectomy group (P <.01). Patients with screen-detected and clinically diagnosed cancer reported similar posttreatment HRQOL. CONCLUSION: Prostatectomy and radiotherapy differed in the type of HRQOL impairment. Because the HRQOL effects may be valued differently at the individual level, patients should be made fully aware of the potential benefits and adverse consequences of therapies for early prostate cancer. Differences in posttreatment HRQOL were not related to the method of cancer detection.


Asunto(s)
Prostatectomía/efectos adversos , Neoplasias de la Próstata/radioterapia , Neoplasias de la Próstata/cirugía , Calidad de Vida , Radioterapia/efectos adversos , Anciano , Estudios de Cohortes , Disfunción Eréctil/etiología , Estado de Salud , Humanos , Masculino , Tamizaje Masivo , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias de la Próstata/psicología , Encuestas y Cuestionarios , Resultado del Tratamiento , Incontinencia Urinaria/etiología
10.
J Clin Oncol ; 16(1): 269-74, 1998 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9440752

RESUMEN

PURPOSE: To validate predictions of the histology (necrosis, mature teratoma, or cancer) of residual retroperitoneal masses in patients treated with chemotherapy for metastatic nonseminomatous testicular germ cell tumor. PATIENTS AND METHODS: We studied 172 testicular cancer patients who underwent resection while tumor markers were normal. Predictive characteristics for the residual histology were registered, including the presence of teratoma elements in the primary tumor, the prechemotherapy level of tumor markers (alpha-fetaprotein [AFP], human chorionic gonadotropin [HCG], lactate dehydrogenase [LDH]), the size of the residual mass, and the percentage of shrinkage in mass diameter. We calculated the predicted probability of necrosis and the ratio of cancer and mature teratoma with previously published logistic regression formulas. RESULTS: The distribution of the residual histology was necrosis in 77 (45%), mature teratoma in 72 (42%), and cancer in 23 (13%). Necrosis could be well distinguished from other tissue, with an area under the receiver operating characteristic (ROC) curve of 82%. No tumor was found in 15 patients with a predicted probability of necrosis over 90%. The predicted probabilities corresponded reliably with the observed probabilities (goodness-of-fit tests, P > .20), although a somewhat higher probability of necrosis was observed in patients treated with chemotherapy containing etoposide. Conversely, cancer could not reliably be predicted or adequately discriminated from mature teratoma. CONCLUSION: The predicted probabilities of necrosis have adequate reliability and discriminative power. These predictions may validly support the decision-making process regarding the need and extent of retroperitoneal lymph node dissection.


Asunto(s)
Modelos Biológicos , Modelos Estadísticos , Neoplasias Retroperitoneales/patología , Neoplasias Retroperitoneales/secundario , Teratoma/patología , Teratoma/secundario , Neoplasias Testiculares/patología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Área Bajo la Curva , Humanos , Masculino , Necrosis , Neoplasia Residual , Reproducibilidad de los Resultados , Neoplasias Retroperitoneales/tratamiento farmacológico , Teratoma/tratamiento farmacológico , Neoplasias Testiculares/tratamiento farmacológico
11.
Eur J Cancer ; 34(14 Spec No): 2232-5, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-10070292

RESUMEN

Survival of adult patients with cancer of the kidney, renal pelvis, ureter and urethra (ICD-9 189) was analysed using data from the EUROCARE II study, a collaborative project of 45 population-based cancer registries in 17 European countries. For the period 1985-1989, more than 24000 patients were included and 5-year relative survival was 48%. Large variations were observed between countries with 5-year relative survival ranging from 57% in France, 53% in Italy and 51% in Spain to 35% in Denmark, 33% in Poland and 30% in Estonia. A number of registries also provided information on previous years and survival was seen to improve with time from 44% in 1978-1980 to 50% in 1987-1989. Age was an important determinant of survival with 5 year survival rates decreasing from 63% in patients aged 15-44 years to 36% in patients aged 75 years and older. Variation in survival rates by country or time is probably related to differences in the distribution of tumour stage at diagnosis. Evidence to confirm this theory is, however, lacking.


Asunto(s)
Neoplasias Renales/mortalidad , Neoplasias Ureterales/mortalidad , Neoplasias Uretrales/mortalidad , Adolescente , Adulto , Distribución por Edad , Anciano , Europa (Continente)/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Sistema de Registros/estadística & datos numéricos , Características de la Residencia , Tasa de Supervivencia
12.
J Cancer Res Clin Oncol ; 118(8): 626-8, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1517284

RESUMEN

In 28 patients with transitional carcinoma of the urinary tract, all treated with chemotherapy, serial measurements of serum tissue polypeptide antigen (TPA) were performed and correlated to clinical evaluations of response. At the start of chemotherapy elevated levels of TPA were found in 4 out of 14 patients with T2-4NO-2MO tumours and in 7 out of 14 patients with distant metastases. In most patients with elevated TPA levels who responded to chemotherapy, TPA levels rapidly returned to normal. False positive elevations of TPA were observed in 2 patients. It is concluded that serial measurement of TPA for monitoring disease activity has limited value because of the low sensitivity of TPA, especially for patients with early-stage cancer, and because of the occurrence of false positive results.


Asunto(s)
Antígenos de Neoplasias/sangre , Biomarcadores de Tumor/sangre , Carcinoma de Células Transicionales/inmunología , Péptidos/sangre , Neoplasias de la Vejiga Urinaria/inmunología , Adulto , Anciano , Carboplatino/uso terapéutico , Carcinoma de Células Transicionales/tratamiento farmacológico , Carcinoma de Células Transicionales/patología , Cisplatino/uso terapéutico , Reacciones Falso Positivas , Femenino , Humanos , Inmunoensayo/métodos , Masculino , Metotrexato/uso terapéutico , Persona de Mediana Edad , Compuestos Organoplatinos/uso terapéutico , Valor Predictivo de las Pruebas , Antígeno Polipéptido de Tejido , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Neoplasias de la Vejiga Urinaria/patología
13.
Am J Clin Pathol ; 78(5): 690-4, 1982 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-7137110

RESUMEN

Soft-agar culture of transitional cell carcinoma colonies from urine, bladder irrigation fluid, and transurethral resection solid tumor specimens demonstrate generally better growth of tumor cell colonies from urine than from irrigation fluid. Growth of tumor colonies from urine was adequate to evaluate presence of tumor and to study growth parameters of the tumor colonies in vitro, although the number of colonies produced from urine was inadequate to evaluate sensitivity or resistance to chemotherapeutic agents. Growth in soft agar of transitional cell carcinoma colonies from urine may offer a simple, noninvasive method of evaluating the effectiveness of therapy and the prognosis for tumor progression.


Asunto(s)
Carcinoma de Células Transicionales/orina , Adulto , Agar , Anciano , Biopsia , Carcinoma de Células Transicionales/patología , Células Cultivadas , Femenino , Humanos , Masculino , Persona de Mediana Edad , Vejiga Urinaria/patología
14.
Urology ; 46(3 Suppl A): 34-40, 1995 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-7544515

RESUMEN

There is no consensus about a case definition of benign prostatic hyperplasia (BPH). In the present study, BPH prevalence rates were determined using various case definitions based on a combination of clinical parameters used to describe the properties of BPH: symptoms of prostatism, prostate volume increase, and bladder outflow obstruction. The aim of this study--in a community-based population of 502 men (55-74 years of age) without prostate cancer--was to determine the relative impact on prevalence rates of the inclusion of these different parameters (and of different cutoff values for these parameters) in a case definition of BPH. There is agreement that age is the dominant determinant of BPH. However, of 28 different case definitions that were formulated, only eight gave a statistically significant increase in the prevalence of BPH with age. The highest overall prevalence of 19% (95% confidence interval [CI], 15-23%) occurred using the definition that combines a prostate volume > 30 cm3 and an International Prostate Symptom Score (IPSS) > 7. The lowest prevalence rate of 4.3% (95% CI, 2-6%) occurred using the definition that combines a prostate volume > 30 cm3, an IPSS > 7, a maximum flow rate < 10 mL/s, and the presence of a postvoid residual urine volume > 50 mL. Thus, prevalence rates depend very much on the parameters used in a case definition. Follow-up will establish which men will eventually request a workup and treatment for BPH and will help determine the best clinical definition of BPH.


Asunto(s)
Tamizaje Masivo , Hiperplasia Prostática/epidemiología , Factores de Edad , Anciano , Humanos , Masculino , Persona de Mediana Edad , Países Bajos/epidemiología , Proyectos Piloto , Prevalencia , Hiperplasia Prostática/diagnóstico , Encuestas y Cuestionarios , Urodinámica
15.
Urology ; 52(2): 237-46, 1998 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9697788

RESUMEN

OBJECTIVES: To compare the discriminatory potential between prostate cancer and benign conditions of the prostate in a population-based screening study, of serum prostate-specific antigen levels (PSA) and PSA corrected for both the total prostate volume (PSA-D) and the transition zone volume (PSA-T). METHODS: In a randomized population-based screening study (Rotterdam section of the European Randomized Study of Screening for Prostate Cancer), in which 10,865 men have been screened, the biopsy results of 1202 men with PSA levels of 4 ng/mL or more were evaluated. Planimetric and prolate ellipsoid volumes of the total prostate as well as of the transition zone were measured. The measured volumes were compared with the volumes of 57 radical prostatectomy specimens through Spearman's rank correlation coefficient and agreement tests. A receiver operating characteristic (ROC) curve analysis was done of sensitivity and specificity of biopsy indications through PSA and PSA corrected for the volumes measured with transrectal ultrasound. RESULTS: In the 1202 men studied, 361 cases of prostate cancer were diagnosed. Both PSA-D and PSA-T showed a significantly higher area under the ROC curve (0.77 and 0.79, respectively) than PSA alone (area 0.65). There was no significant difference between PSA-D and PSA-T. The use of a PSA-D threshold value of 0. 10 ng/mL/cc would have avoided 28% of biopsies at the cost of 10% of detectable cancers. A PSA-D threshold of 0.15 ng/mL/cc would have avoided 73.8% of biopsies at the cost of not diagnosing 43.8% of detectable cancers. CONCLUSIONS: The planimetrically obtained prostate volume showed a more favorable agreement with the radical prostatectomy volume than the prolate ellipsoid volume. The discriminatory potential of the corrected PSA value is better at predicting the results of needle biopsy of the prostate when compared with PSA alone. The use of the transition zone volume for this correction results in a higher discriminatory potential when compared to the use of the total prostate volume; however, the observed difference was not statistically significant.


Asunto(s)
Antígeno Prostático Específico/sangre , Próstata/patología , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/patología , Anciano , Diagnóstico Diferencial , Humanos , Masculino , Persona de Mediana Edad , Prostatectomía , Neoplasias de la Próstata/cirugía , Curva ROC
16.
J Med Screen ; 4(2): 102-6, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9275269

RESUMEN

OBJECTIVES: To assess motives for attending a randomised population based prostate cancer screening trial, and to assess acceptance of screening and invitation procedures. METHODS: First pilot of the European Randomised Study of Screening for Prostate Cancer (ERSPC; 1992/1993). Men aged 55-75 years, randomly selected from the population register of four city districts of Rotterdam, were invited by a single invitation for screening. Screening consisted of prostate specific antigen prescreening followed by either (1) digital rectal examination, transrectal ultrasound, and, on indication, biopsy, or (2) no additional screening. After screening, or in the case of non-attendance, a questionnaire was sent to a random sample of 600 attenders and 400 non-attenders, with a reminder after three weeks. OUTCOME MEASURES: In both attenders and non-attenders: knowledge of prostate cancer, attitudes towards screening, motives for attending, procedural aspects and sociodemographic characteristics. In attenders, acceptance of screening procedures. RESULTS: The response rate for the questionnaire was 76%: 94% in attenders and 42% in non-attenders. The main reasons for attending were expected personal benefit (76%) and scientific value (39%), and those for not attending were absence of urological complaints (41%) and anticipated pain or discomfort (24%). Uptake of screening was 32%, which increased to a sustained 42% in following years. Attenders, compared with non-attenders, were significantly younger, more often married, better educated, and had higher perceived health status, more knowledge about prostate cancer, and a more positive attitude towards screening. Information materials and invitation procedures were well accepted (high report marks and satisfaction, and 95% would attend for rescreening). A single prostate specific antigen determination was liked less than a combination of all three screening modalities. CONCLUSIONS: (1) The main reasons for attending are personal benefit and science, and those for not attending were absence of urological complaints and anticipated pain or discomfort; (2) knowledge, attitudes, and motives for attending are comparable with other screening programmes; hence, for population based prostate cancer screening, known health promotional aspects should be carefully considered; (3) prostate specific antigen, digital rectal examination and transrectal ultrasound are acceptable to attenders.


Asunto(s)
Tamizaje Masivo/psicología , Tamizaje Masivo/estadística & datos numéricos , Motivación , Neoplasias de la Próstata/epidemiología , Neoplasias de la Próstata/prevención & control , Anciano , Actitud Frente a la Salud , Conocimientos, Actitudes y Práctica en Salud , Humanos , Masculino , Persona de Mediana Edad , Países Bajos , Proyectos Piloto , Clase Social , Encuestas y Cuestionarios
17.
Am J Clin Oncol ; 20(2): 111-9, 1997 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-9124181

RESUMEN

Adenocarcinoma of the prostate (CaP) in the Western world has become the most common noncutaneous human tumor. CaP is also the second most important cause of cancer deaths among the male population in the United States. Major progress was made in the past decade in better understanding this disease process, as well as in improved diagnostic accuracy. This improved diagnostic accuracy was due to wide application of prostate-specific antigen (PSA), use of transrectal ultrasound (TRUS), and greater awareness among clinicians of CaP. The use of PSA in clinical practice has resulted in a sharp increase in the number of patients diagnosed with capsule-confined tumors. The optimal treatment for capsule-confined CaP is in the process of being defined. Radical prostatectomy in the United States is currently the most commonly applied treatment for younger patients. Excellent treatment results with a 10-year actuarial survival > 80% are readily obtainable in properly selected patients. Nerve-sparing procedures helped reduce the high incidence of impotence that occurs in patients after radical retropubic prostatectomy. Radiotherapy remains the other curative treatment method in the management of CaP patients, with long-term survival rates similar to those reported in surgical series. Due to the problem of frequent preoperative tumor understaging, a routine use of postoperative irradiation to the prostatic fossa produces an excellent (> 95%) incidence of local tumor control. Management of patients with metastatic disease has undergone a considerable evolution with the development of modern hormonal management and treatment with strontium-89 to control intractable bone pain. Newer treatment methods such as hyperthermia are currently being investigated. Major efforts are directed toward the reduction of short- and long-term treatment toxicity associated with surgery, radiotherapy, and hormonal management, thus improving patient quality of life.


Asunto(s)
Adenocarcinoma/terapia , Neoplasias de la Próstata/terapia , Adenocarcinoma/diagnóstico , Adenocarcinoma/radioterapia , Adenocarcinoma/cirugía , Braquiterapia , Manejo de la Enfermedad , Humanos , Hipertermia Inducida , Inmunoterapia , Masculino , Antígeno Prostático Específico/sangre , Prostatectomía , Neoplasias de la Próstata/diagnóstico , Neoplasias de la Próstata/radioterapia , Neoplasias de la Próstata/cirugía , Radioterapia Adyuvante
18.
Arch Pathol Lab Med ; 107(2): 81-3, 1983 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-6687424

RESUMEN

Human carcinoma tissues were grown in culture for two to four weeks using the two-layer soft agar technique. All cultures that showed growth of tumor cell colonies also showed well-preserved, apparently healthy tumor cells lying singly. These cells showed neither proliferative capacity nor necrosis or morphologic degeneration during the time in soft agar. Thus, morphologic criteria seem to be poor indicators of tumor cell proliferative potential, at least in the short term. However, the method of soft agar tumor clonogenic cell culture itself provided a direct measure of tumor cell proliferative capacity, ie, the formation of colonies from single tumor cells. This may be valuable in directly assessing the presence of "viable" tumor cells in biopsy specimens taken after therapy, and thus guide further patient therapy.


Asunto(s)
Carcinoma/patología , Agar , Anciano , Transformación Celular Neoplásica/patología , Células Cultivadas , Femenino , Humanos , Masculino
19.
Urology ; 68(3): 615-20, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17010732

RESUMEN

OBJECTIVES: To evaluate the tumor characteristics and prognostic factors in screen-detected prostate cancers in two successive screening rounds with a 4-year screening interval in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. METHODS: From 1993 to 2000, 42,376 men (21,210 in the screening arm and 21,166 in the control arm) were randomized and screened. Prostate-specific antigen testing, digital rectal examination, transrectal ultrasonography, and sextant biopsies were offered to the participants in the screening arm. A total of 1218 men with a biopsy indication at the first screening received an additional screening after 1 year (early recall). By 2004, all men had received their second screening. Interval carcinomas were defined as cancers detected during the screening interval and were identified by linkage with the Cancer Registry. RESULTS: In the first round, 1014 prostate cancers were detected--24 in the men noncompliant to screening, 63 at the early recall screening, and 433 in the second round of screening. Also, 62 interval carcinomas were diagnosed. In the second screening round, the mean prostate-specific antigen value was lower (5.6 versus 11.1 ng/mL), advanced clinical stage T3-T4 was 7.1-fold less common, and 76.4% versus 61.5% of the biopsy Gleason scores were less than 7. In the first screening round, 13 regional and 9 distant metastases were detected; in the second round, 2 cases with distant metastasis were found. CONCLUSIONS: Overall, a shift toward more favorable tumor characteristics was seen for the second round of screening. These results support the screening methods used and the interscreening interval of 4 years.


Asunto(s)
Neoplasias de la Próstata/diagnóstico , Anciano , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Neoplasias de la Próstata/epidemiología , Factores de Tiempo
20.
Urol Res ; 25 Suppl 2: S53-6, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9144887

RESUMEN

Over the past few decades it has become clear that prostate cancer is a serious health problem in elderly men. The population of most Western countries is ageing and the number of deaths from prostate cancer patients is increasing. The most promising way to deal with this problem seems to be through early detection of the disease, which can be accomplished through case finding and screening of the male population at risk. The basic purpose of screening for a given disease is to separate from a large group of apparently healthy individuals those who have a high probability of having the disease under study. These individuals may be given a diagnostic workup, and if the diagnosis is established they can be brought to treatment. The concept of prostate cancer screening, however, is an extensively debated issue. The limited knowledge of the natural history, uncertainties about the effectiveness of treatment in reducing mortality and the adverse effects of treatment lead to fear of overdiagnosis and subsequent overtreatment. Routine application of screening for prostate cancer should not take place before the results of multicentre prospective randomised studies demonstrate a reduction in prostate cancer mortality through screening of the male population.


Asunto(s)
Tamizaje Masivo/métodos , Neoplasias de la Próstata/prevención & control , Adulto , Anciano , Anciano de 80 o más Años , Sesgo , Humanos , Masculino , Tamizaje Masivo/estadística & datos numéricos , Persona de Mediana Edad , Estudios Multicéntricos como Asunto , Neoplasias de la Próstata/diagnóstico , Neoplasias de la Próstata/terapia , Ensayos Clínicos Controlados Aleatorios como Asunto , Sensibilidad y Especificidad , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA